David Wolinsky, MD joined the staff at Cleveland Clinic Florida in 2011. He is presently Section Head of nuclear cardiology and Medical Director of cardiac rehabilitation. More recently, he developed the cardiac amyloid clinic for which he remains director. Under his leadership the clinic has become the largest of its kind in South Florida.
Dr. Wolinsky is a graduate of Columbia University where he received his undergraduate and medical degrees. He carried out his postgraduate training and was on staff at St. Luke’s Hospital in New York City for seven years before joining Albany Associates in Cardiology in Albany, New York where he worked as director of the nuclear cardiology programme, which he founded, and also served as director of the heart failure and cardiac rehabilitation and wellness programmes.
Dr. Wolinsky is a founding member of the American Society of Nuclear Cardiology. He was a member of the Board of Directors and the Executive Committee and served as President in 2015. Dr. Wolinsky has been Chair of the Health Policy Committee since 2018 where he focuses on developing alliances that promote optimal utilisation of noninvasive imaging to provide maximal value in the modern healthcare paradigm. He is Chair of the task force that has developed Refer Wisely, joint initiative of the American Society of Nuclear Cardiology and the American College of Physicians to provide education regarding the appropriate use of diagnostic imaging with a specific focus on the appropriate use of myocardial perfusion imaging.
More recently Dr. Wolinsky has focused much of his clinical work on cardiac amyloidosis. He has established a multidisciplinary programme for the management of amyloidosis that is managing over 250 patients. He is involved in early diagnosis, nuclear imaging, and treatment of the disease. Dr. Wolinsky developed the scintigraphic imaging programme for cardiac amyloidosis and has helped multiple nuclear cardiology labs improve their testing. He has participated in multiple clinical trials and research projects aimed at a better understanding of cardiac amyloidosis.